Patient Support Services Contact Us
Expanding Our Mission to Immuno-oncology
More choice without compromise

Building on our success with UDENYCA® (pegfilgrastim-cbqv), we are now expanding our mission to immuno-oncology with Junshi Biosciences’ novel anti-PD-1 antibody, toripalimab.

Toripalimab is an investigational new drug currently being evaluated by the FDA for commercial distribution in the United States.

I-O Begins Here: Late-Stage Anti-PD-1 Antibody

Our foundational first step in immuno-oncology begins with Junshi Biosciences’ anti-PD-1 antibody.

Learn More

Expanded Mission. Expanded Pipeline.

Our expanded immuno-oncology pipeline will be funded with cash flows generated by our commercial biosimilar business.

Learn More
Dr. Samuel Nussbaum

Coherus BioSciences Mourns the Passing of Board Member Alan C. Mendelson

“Alan was truly a titan of the biotech industry, without peer in his discipline, and this is such tremendous loss on so many levels for so many people. His contributions and impact on the industry through its genesis and evolution are difficult to overstate. I am honored to have had him as a decades-long personal friend, inspiring mentor, and the most trusted of advisors. Alan tenaciously advocated for Coherus from the start and through all subsequent phases of the Company’s evolution. His influence on our company is profound, and we are grateful for his wise counsel. On behalf of the entire Coherus team and our Board of Directors, I offer our deep and heartfelt condolences to the Mendelson family.”—Denny Lanfear, CEO of Coherus.

Latest News

Coherus and Junshi Biosciences Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer

Learn More

Coherus BioSciences Announces New Employment Inducement Grants

Learn More

Coherus BioSciences Reports Third Quarter 2021 Results

Learn More

Coherus issues white paper supporting “Securing America’s Medicines & Supply”

View Now